Change in vital parameters at first methylphenidate administration as a predictor of treatment response at six-month follow-up

Methylphenidate is the primary pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), yet approximately 30% of patients show a poor clinical response. Currently, no reliable biomarkers exist to predict which patients will benefit from treatment. Emerging evidence suggests that methylphenidate-induced increases in blood pressure are associated with improvements in attention and underlying neurobiological mechanisms. Blood pressure could thus serve as a low-cost, accessible…

via https://pubmed.ncbi.nlm.nih.gov/40879766/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20250905010905&v=2.18.0.post9+e462414